Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer
Fig 3
Lapatinib and poziotinib demonstrate anti-proliferative synergy when combined with paclitaxel.
(A) A panel of TKIs were screened for anti-proliferative synergy when combined with paclitaxel on TOV-21G-control and–PacR derivative cell lines. The ABCB1-specific inhibitor, elacridar, was included as a positive control. Average Bliss synergy scores across drug combinations (minimum of 3 independent experiments) are summarized as averages +/- standard error of the mean. Unpaired two-tailed t-tests were performed for each drug (control vs. PacR; * p < 0.05; ** p < 0.005; *** p < 0.0005). (B) Representative surface response model plots of synergy analyses using a Bliss independence model for paclitaxel in combination with lapatinib are depicted for control and PacR TOV-21G and (C) OVCAR3 cell lines.